Health care stocks were advancing pre-bell Thursday as the iShares Biotechnology ETF (IBB) was marginally higher and the Health Care Select Sector SPDR Fund (XLV) was up 0.1% recently.
ClearPoint Neuro (CLPT) shares were up nearly 10% after the company said the US Food and Drug Administration has granted De Novo marketing authorization for its SmartFlow Neuro Cannula for the delivery of PTC Therapeutics' Kebilidi gene therapy to targeted regions within the brain.
PTC Therapeutics (PTCT) shares were over 2% higher after the company said the US Food and Drug Administration has accelerated approval of Kebilidi, the company's gene therapy for aromatic L-amino acid decarboxylase deficiency.
BeiGene (BGNE) shares were 0.8% higher after the company said it plans to change its name to BeOne Medicines, subject to shareholder approval.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。